Kisplyx (Lenvatinib)

Lenvatinib blocks multiple receptor tyrosine kinases such as VEGFR1‑3, FGFR1‑4, PDGFRα, KIT and RET. By inhibiting these signalling pathways, it reduces angiogenesis, limits tumour blood‑supply, and directly suppresses tumour cell proliferation, leading to slowed tumour growth and possible regression.

The prescribed dose of Kisplyx is determined by the treating physician based on the specific cancer type, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for lenvatinib in pregnancy and lactation are limited. The drug is generally avoided in pregnant or nursing women because potential risks to the fetus or infant are unknown. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation as advised by their clinician.

To request Kisplyx, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to lenvatinib in many indications is sorafenib, another multi‑kinase inhibitor. While both target VEGFR pathways, lenvatinib additionally inhibits FGFR1‑4, which may offer broader anti‑angiogenic activity. Clinical trials have shown differences in efficacy and side‑effect profiles, so the choice depends on the specific tumour type, patient tolerance and physician judgment.

Kisplyx tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and excessive heat. Do not refrigerate or freeze the tablets.

Kisplyx is taken orally as a whole tablet with a glass of water. It is usually taken once daily, preferably at the same time each day, and may be taken with or without food as directed by the prescriber. Swallow the tablet whole; do not crush or chew it.

Serious adverse events associated with lenvatinib include hepatotoxicity (significant liver enzyme elevation or liver failure), cardiac failure (shortness of breath, swelling, reduced exercise tolerance), severe haemorrhage (gastrointestinal or intracranial bleeding), and gastrointestinal perforation. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Kisplyx should not be used in patients with severe hepatic impairment, uncontrolled hypertension, or known hypersensitivity to lenvatinib or any tablet excipients. It is also contraindicated during pregnancy and breastfeeding, and should be avoided in individuals with a history of serious bleeding or recent major surgery unless the prescriber decides otherwise.